🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparative Evaluation of the Efficacy and Safety of High-Power Short-Duration Radiofrequency Ablation and Standard Low-Power Ablation in Catheter Treatment of Atrial Fibrillation

RecruitingNAAges 18 Years - 70 YearsAllBakulev Scientific Center of Cardiovascular Surge…
NCT07728539 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Atrial fibrillation (AF) is the most common cardiac arrhythmia and represents one of the leading causes of cardiovascular morbidity and mortality. According to current data, AF is associated with approximately 20% of all ischemic strokes, while the risk of stroke in patients with this arrhythmia is increased fivefold. Ischemic stroke in patients with AF is characterized by a more severe clinical course, more frequently results in death, is associated with significant disability, and carries a higher risk of recurrence compared with strokes of other etiologies. Consequently, the risk of death in patients with AF-associated stroke is doubled, while the economic costs of treatment increase by an average of 1.5 times. The aim of the present study is to perform a comparative evaluation of the efficacy of two interventional treatment strategies for atrial fibrillation: very high-power short-d

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age over 18 years old; * Atrial fibrillation resistant to antiarrhythmic therapy; * Paroxysmal form of atrial fibrillation; * Persistent form of atrial fibrillation; * The patient's consent to participate in the study. Exclusion Criteria: Exclusion Criteria: * Age under 18 and over 80 years old; * The presence of another cardiac pathology requiring surgical treatment; * Congenital heart defects; * Previous "open" cardiac surgery; * Bone marrow diseases; * Pathology of the blood coagulation system; * The left ventricular ejection fraction is less than 40%; * Moderate to severe renal insufficiency (creatinine clearance \<50 ml/min); * Drug-resistant hypertension (despite hypotensive therapy); * Organically altered mitral valve; * There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons; * The patient's participation in another clinical trial.
💊

What it tests

  • Technique of radiofrequency ablation using very high-power short-duration ablation parameters
  • Technique of radiofrequency ablation using low-power settings
📍

Where

1 site
Bakulev National Medical Research Center for Cardiovascular Surgery
Moscow, Russia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy